SLNO Soleno Therapeutics, Inc.
Healthcare$53.01+0.00%OpenMarket Cap: $2.76B
As of 2026-05-26
Valuation
P/E (TTM)
134.60
PEG
1.20
P/B
5.57
P/S
9.69
EV/EBITDA
25.68
DCF Value
$152.98
FCF Yield
3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.6%
Operating Margin
30.8%
Net Margin
33.7%
ROE
22.9%
ROA
15.8%
ROIC
15.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $94.6M | 98.7% | $31.8M | $31.4M | $— | — |
| Q4 null | $91.7M | 99.1% | $40.4M | $43.4M | $— | — |
| FY null | $190.4M | 98.6% | $14.9M | $20.9M | $— | — |
| Q3 null | $66.0M | 98.3% | $22.1M | $26.0M | $— | — |
| Q2 null | $32.7M | 97.9% | $-6.5M | $-4.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-45.7M | $-43.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-59.1M | $-56.0M | $— | — |
| FY null | $0.00 | NaN% | $-187.7M | $-175.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-80.2M | $-76.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-23.2M | $-21.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-23.5M | $-21.4M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-13.9M | $-11.3M | $-0.43 | — |